Aurora inhibitor 1 is primarily utilized in the field of oncology for its potential to target and inhibit Aurora kinases, which are enzymes involved in cell division and proliferation. By blocking these kinases, it disrupts the growth and division of cancer cells, making it a promising candidate for cancer therapy. It is particularly studied in the context of solid tumors and hematological malignancies, where uncontrolled cell division is a hallmark. Researchers are exploring its efficacy in combination with other chemotherapeutic agents to enhance treatment outcomes. Additionally, it is being investigated for its role in overcoming drug resistance in certain cancers, offering a potential pathway for more effective therapeutic strategies.